A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

NCT05526755 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

188

Enrollment

INDUSTRY

Sponsor class

Conditions

Stage II-IIIB Non-small Cell Lung Carcinoma

Interventions

DRUG: Osimertinib 80 mg/40 mg

Sponsor

AstraZeneca